Yet another study coming out connecting anti-inflammatory medication to a reduction in multiple sclerosis progression. The University of Chicago finds Guanabenz, a high blood pressure medication, when taken at the peak of a multiple sclerosis attack reduces the severity of the next attack by 50% and results in “less myelin loss and cell death.” (NeurologyTimes.com) Trials are on-going in mice replicating the findings. It is only a matter of time before an anti-inflammatory supplemental treatment is honed for multiple sclerosis. Hurry please, I’m losing myelin now!
